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Nephrotic syndrome (NS) rarely occurs after hematopoietic stem cell transplanta-
tion (HSCT) as a late manifestation of graft-versus-host disease (GVHD). Herein, we
report a case of HSCT-associated membranous nephropathy in a female patient
with aplastic anemia. The patient received an allogeneic HSCT from her human
leukocyte antigen-identical brother following myeloablative conditioning che-
motherapy. NS occurred 21 months after HSCT without any concurrent features
of chronic GVHD. The patient was treated with prednisolone and cyclosporine after
renal biopsy conﬁrmed membranous nephropathy, and achieved complete remis-
sion. Our report contradicts previous assumptions that concomitant chronic GVHD
is responsible for the development of NS, suggesting that NS can develop as a new,
independent manifestation of GVHD.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an established treatment for hematologic malignancy,
and more than 15,000 procedures are performed worldwide
each year [1]. After HSCT, chronic graft-versus-host disease
(cGVHD) is the most common cause of morbidity and mortal-
ity. Indeed, the incidence of cGVHD is reported to be 60–80%
during long-term follow-up [2], and the incidence has recently
been increasing because of the extensive use of unrelated
donor transplants, older donor age, increased use of donor
leukocyte infusion, and peripheral blood stem cell transplanta-
tion (PBSCT) [3]. Symptoms of cGVHD can vary depending onrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
al Medicine, Yonsei
Seodaemun-gu, Seoul,the site of involvement, which may include the skin, eyes,
oropharynx, or respiratory and gastrointestinal tracts. How-
ever, renal involvement associated with GVHD, particularly
glomerulopathy, is very rare. In general, renal injury after HSCT
occurs due to hemodynamic compromise, medications, radia-
tion, or thrombotic microangiopathy [4], which manifests as
tubulointerstitial nephropathy. Cases of nephrotic or nephritic
syndrome after HSCT have recently been reported, and these
glomerulopathies are presumably related to cGVHD. Herein,
we report a case of membranous nephropathy (MN) in a
patient who underwent HSCT 21 months before this unusual
nephrotic syndrome (NS) developed.Case report
A 39-year-old female patient was admitted to our hospital due
to generalized edema and fatigue. The patient was diagnosedublished by Elsevier. This is an open access article under the CC BY-NC-
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diabetes or hypertension. Most importantly, she had undergone
allogeneic PBSCT from her human leukocyte antigen-identical
brother 21 months before admission following myeloabla-
tive conditioning chemotherapy with cyclophosphamide and
anti-thymoglobulin. Grade IV acute gastrointestinal GVHD
accompanied by diarrhea developed 12 days after transplan-
tation despite GVHD prophylaxis with cyclosporine, metho-
trexate, and steroids, for which a continuous maintenance
regimen of cyclosporine and prednisolone resulted in resolu-
tion. The patient also suffered from cytomegalovirus colitis
4 months after transplantation, and recovered after a 2-week
administration of gancyclovir while cyclosporine was discon-
tinued and prednisolone was tapered to 5 mg/day. Eighteen
months after cytomegalovirus infection, the patient suddenly
developed generalized edema and gained 5 kg of body weight
over a 2-week period.
At this time physical examination revealed 3þ pitting
edema of the lower extremities. Initial laboratory tests
showed the following values: hemoglobin, 10.5 g/dL; plate-
lets, 320109/L; serum albumin, 2.2 g/dL; total cholesterol,
402 mg/dL; low-density lipoprotein cholesterol, 248 mg/dL;
serum creatinine, 0.77 mg/dL; random urine protein-to-
creatinine ratio (UPCR), 7.85 g/g; and 24-hour urinary protein
excretion, 5.03 g/day. Hepatitis B surface antigen, hepatitis C
antibody and anti-nuclear antibody titers were undetectable,
and serum concentrations of C3, C4, and immunoglobulins G,
A, and M were within reference range.
Renal biopsy was performed 3 days after admission. On
light microscopy (Fig. 1A), eight nonsclerotic glomeruli were
normocellular without mesangial expansion. The glomerular
basement membrane was not thickened and double contours
or subepithelial spikes were not noted. The interstitium was
moderately inﬁltrated by mononuclear inﬂammatory cells,Figure 1. Pathologic ﬁndings in a patient with membranous nephropath
shows normal appearance of glomeruli without thickened basement memb
identiﬁes CD3þ , suggesting inﬁltration of T cells in the interstitium (original
pattern of IgG (2þ) deposition along the peripheral capillary wall. (D) Electr
subepithelial space.which immunohistochemical staining conﬁrmed as CD3þ
T cells (Fig. 1B). Immunoﬂuorescence studies showed a
granular pattern of IgG (2þ) (Fig. 1C). Electron microscopy
demonstrated numerous nodular electron-dense deposits that
were mainly located in the subepithelial space along with
diffusely effaced epithelial foot processes (Fig. 1D).
These pathologic ﬁndings were consistent with Grade II MN.
As such, oral prednisolone at a dose of 1 mg/kg was immediately
started, and an 8-week treatment resulted in partial remission
with a UPCR of 1.9 g/g. Because the patient was intolerant to the
side effects of corticosteroid treatment, prednisolone was
tapered. Two weeks later, however, the random UPCR increased
to 7.58 g/g; thus, cyclosporine at a dose of 5 mg/kg was added.
Complete remission was achieved as demonstrated by a UPCR of
0.23 g/g 4 months after the combined treatment with cyclos-
porine and 10 mg/day of low-dose prednisolone.Discussion
Acute kidney injury (AKI) is a common complication in
patients with allo-HSCT. In general, AKI can be attributed to
preexisting renal disease, underlying malignancy, previous
chemotherapies, irradiation, and various nephrotoxic agents
such as antimicrobials, antifungals, and antivirals [5]. Accord-
ingly, acute tubular necrosis, hemolytic uremic syndrome,
thrombotic microangiopathy, and radiation nephritis are the
most common forms of AKI after HSCT. However, glomerulo-
pathy such as NS or nephritis rarely occurs as a manifestation
of cGVHD.
The notion that graft-versus-host reaction is directly related
to glomerular injury has recently been gaining acceptance.
However, the clinical characteristics of HSCT-associated glo-
merulopathy are not well deﬁned. Several studies conductedy as a manifestation of graft versus host disease. (A) Light microscopy
rane (original magniﬁcation 400). (B) Immunohistochemical staining
magniﬁcation 100). (C) Immunoﬂuorescence staining shows granular
on microscopy shows numerous nodular electron-dense deposits in the
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One of these reports showed that nine of 889 patients who
underwent allo-HSCT from 1994 to 2002 developed NS, with
an overall incidence of 1% [8]. When only sibling transplant
patients with or without cGVHD were taken into account, the
incidence of NS was 1.8% and 0.6%, respectively [8], suggesting
that it is not a common complication. Glomerular diseases tend
to occur in allogeneic PBSCT patients from unrelated donors
who received nonmyeloablative therapy shortly after immu-
nosuppression was decreased or stopped [9,10], and the
median time elapsed to the onset of NS from cessation of
immunosuppression was 1.5 months [9]. Regarding pathologic
features, MN (61%) was the most common type of NS, followed
by minimal change disease (22%) [7]. Approximately 70% of
patients had concomitant cGVHD at the onset of NS and, in
particular, 75–93% of patients with postHSCT MN had recent or
current cGVHD [1,9]. In addition, development of NS appears to
be a late event after HSCT because NS was diagnosed 15.5–24
months after HSCT [8].
In line with these ﬁndings, our patient developed NS 21
months after allogeneic PBSCT, whereby MN was conﬁrmed
by renal biopsy. Unlike previous observations, the patient did
not show other features of cGVHD before the onset of NS,
although she did experience acute GVHD 12 days after HSCT.
However, a prior episode of acute GVHD is unlikely to be
related to the development of glomerular disease considering
its late onset after HSCT [9]. Despite the high incidence
of cGVHD, only a small portion of patients with cGVHD
developed glomerular disease, and this low incidence is no
different than that of the whole HSCT population [8,11].
Furthermore, cGVHD was not evident in approximately 30%
of patients who presented with NS [9], suggesting that NS can
develop irrespective of GVHD. In this regard, it is not clear
whether preexisting cGVHD can indeed contribute to the
development of glomerular disease. Nevertheless, in this case,
immunohistochemical studies clearly identiﬁed T cells in
the interstitium. Because complete donor chimerism was
conﬁrmed, these T cells originated from the donor and were
presumed to be associated with kidney injury. This ﬁnding
may be nonspeciﬁc because kidney injury could be caused by
other conditions such as drugs or infections. However, con-
sidering the fact that the patient had no evidence of kidney
injury associated with such conditions before the onset of NS,
this pathologic ﬁnding partly explains the presence of GVHD
in the kidney.
Our patient developed NS while 5 mg/day of prednisolone
was maintained. Previous observations showed that NS
usually occurred shortly after immunosuppressive medica-
tions were stopped or their dose was reduced [9]. However, it
is uncertain whether cessation or reduction of immunosup-
pression may play a role in the development of NS. In fact,
40% of patients that have NS may develop glomerular disease
while on immunosuppressive agents [9].
Although controversy remains over the role of preexisting
cGVHD in postHSCT NS, it has been suggested that immune
complex, which is formed as a result of GVHD, can deposit
within the glomeruli and cause damage. In particular, auto-
antibody formation has been detected in both human and
experimental cGVHD [12]. In addition, B-cell dysregulation
with a high prevalence of autoantibodies to cellular antigens
and minor histocompatibility antigens has been demon-
strated in patients with cGVHD [12–15]. Besides B-cell
dysregulation, alloreactive T cells are also implicated inHSCT-associated NS. In fact, cGVHD is considered an immune
reaction between donor CD4þ/Th2 cells and the recipient’s
minor histocompatibility complex antigens. Furthermore,
preHSCT conditioning chemotherapy or irradiation can cause
renal damage, which renders hiding autoantigen exposed or
altered, ultimately leading to selective activation of alloreac-
tive donor CD4þ cells and the production of immune com-
plex [1]. The pathogenesis of HSCT-associated NS cannot
be explained by a single factor, and is more likely to
be attributed to the combination of B cell dysregulation,
alloreactive T cells, preconditioning chemotherapy, etc.
Treatment of HSCT-associated NS has not yet been deﬁned,
but, similar to idiopathic NS, corticosteroids and cyclosporine
have been most commonly used [7]. Other immunosuppres-
sive agents such as cyclophosphamide, mycofenolate mofetil,
and rituximab have also been attempted to induce remission.
Overall responsiveness to these drugs appears favorable:
according to a previous report, 27% and 62% of patients with
MN attained complete and partial remission, respectively, and
90% of patients with minimal change disease achieved com-
plete remission[7]. Likewise, in our case, cyclosporine in
addition to corticosteroids resulted in complete resolution of
proteinuria, and the patient has been in complete remission.
In conclusion, we present a case of postHSCT MN as a rare
manifestation of GVHD. However, NS occurred without other
features of cGVHD while the patient was on low-dose corti-
costeroids. Our report contradicts previous assumptions that
concomitant GVHD is responsible for the development of
NS, suggesting that NS can develop as a new, independent
manifestation of GVHD.Conﬂict of interest
None.
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